Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Establishing isogenic pluripotent stem cell-based models for OPA1 mutation-caused dominant optic atrophy
Author Affiliations & Notes
  • Xian-Jie Yang
    Ophthalmology, UCLA Stein Eye Institute, Los Angeles, California, United States
  • Katherine Pohl
    Ophthalmology, UCLA Stein Eye Institute, Los Angeles, California, United States
  • Xiangmei Zhang
    Ophthalmology, UCLA Stein Eye Institute, Los Angeles, California, United States
  • Johnny Ji
    Ophthalmology, UCLA Stein Eye Institute, Los Angeles, California, United States
  • Duc Hoang
    Ophthalmology, UCLA Stein Eye Institute, Los Angeles, California, United States
  • Benjamin Smith
    Ophthalmology, UCLA Doheny Eye institute, Acadia, California, United States
  • Steven A Barnes
    Ophthalmology, UCLA Doheny Eye institute, Acadia, California, United States
  • Footnotes
    Commercial Relationships   Xian-Jie Yang None; Katherine Pohl None; Xiangmei Zhang None; Johnny Ji None; Duc Hoang None; Benjamin Smith None; Steven Barnes None
  • Footnotes
    Support  NIH R01EY026319, CIRM DISC2-13475, NIH F31EY033242, NIH 5T32EY007026, NIH core grant P30EY000331, RPB unrestricted grant to UCLA
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4520. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xian-Jie Yang, Katherine Pohl, Xiangmei Zhang, Johnny Ji, Duc Hoang, Benjamin Smith, Steven A Barnes; Establishing isogenic pluripotent stem cell-based models for OPA1 mutation-caused dominant optic atrophy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4520.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The majority of dominant optic atrophy (DOA) is caused by mutations in the OPA1 gene that encodes a mitochondrial targeted protein playing important roles in mitochondrial dynamics, membrane integrity, cristae structure, and cellular respiration. Despite its expression in most somatic tissue types, OPA1 mutations most prominently affect retinal ganglion cells (RGCs). The purpose of the study is to use pluripotent stem cell (PSC)-derived retinal organoids to overcome the scarcity of human RGCs and establish DOA disease models in vitro.

Methods : The peripheral blood cells of DOA patients with distinct OPA1 mutations were reprogrammed to obtain iPSC lines. CRISPR-Cas mediated homologous directed repair (HDR) was subsequently performed to correct the mutation of a DOA patient’s iPSCs to establish an isogenic control iPSC line. In addition, CRISPR-Cas9-mediated gene editing was used to create homozygous and heterozygous OPA1 mutant ESCs from a control line with a normal OPA1 gene. The OPA1 mutant and control PSC lines, and 3D retinal organoids derived from these PSCs were characterized for protein expression by Western blot, mitochondrial morphology by super resolution imaging, cellular respiration by Seahorse assay, and neuronal properties by whole cell patch clamp recording.

Results : We have established isogenic OPA1 mutant and control PSC lines. The OPA1 mutant PSCs show reduced OPA1 protein expression, altered mitochondrial morphology, and reduced cell respiration and mitochondrial ATP production rates compared with their isogenic controls. All heterozygous OPA1 mutant PSC lines can give rise to retinal organoids and produce RGCs. Retinal organoids show different OPA1 protein isomer ratios compared with PSCs. Similar reduced cellular respiration and ATP production rates have been observed in OPA1 mutant retinal organoids compared with their corresponding isogenic controls. Electrophysiological analysis of OPA1 mutant and control PSC-derived neurons has detected altered physiological properties between isogenic pairs.

Conclusions : The isogenic OPA1 mutant and control PSC lines provide useful tools for establishing OPA1-DOA disease models using 3D-retinal organoid-derived RGCs and induced neurons. The identified OPA1 mutant phenotypes serve as the basis for using PSC-based DOA disease models in vitro to develop therapies.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×